AbbVie Closed Another Humira Biosimilar Deal with Pfizer

See The Pharma Letter to learn more about a recent deal where AbbVie licensed biosimilar adalimumab to Pfizer. Under the deal terms, AbbVie will grant Pfizer a non-exclusive license on specified dates to AbbVie’s intellectual property relating to TNF inhibitor Humira...

Pin It on Pinterest